NASDAQ:MTVA MetaVia (MTVA) Stock Price, News & Analysis $1.78 0.00 (0.00%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$1.76 -0.02 (-0.84%) As of 07:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About MetaVia Stock (NASDAQ:MTVA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MetaVia alerts:Sign Up Key Stats Today's Range$1.65▼$1.8050-Day Range$0.97▼$3.8552-Week Range$0.97▼$19.03Volume129,086 shsAverage Volume193,318 shsMarket Capitalization$9.18 millionP/E RatioN/ADividend YieldN/APrice Target$20.00Consensus RatingHold Company Overview MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass. Read More MetaVia Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreMTVA MarketRank™: MetaVia scored higher than 60% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingMetaVia has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialMetaVia has a consensus price target of $20.00, representing about 1,023.6% upside from its current price of $1.78.Amount of Analyst CoverageMetaVia has only been the subject of 2 research reports in the past 90 days.Read more about MetaVia's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for MetaVia are expected to decrease in the coming year, from ($2.78) to ($3.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MetaVia is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MetaVia is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMetaVia has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about MetaVia's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.42% of the float of MetaVia has been sold short.Short Interest Ratio / Days to CoverMetaVia has a short interest ratio ("days to cover") of 0.61, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MetaVia has recently decreased by 70.10%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMetaVia does not currently pay a dividend.Dividend GrowthMetaVia does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.58 News SentimentMetaVia has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for MetaVia this week, compared to 3 articles on an average week.MarketBeat Follows2 people have added MetaVia to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MetaVia insiders have not sold or bought any company stock.Percentage Held by Insiders0.60% of the stock of MetaVia is held by insiders.Percentage Held by Institutions1.37% of the stock of MetaVia is held by institutions.Read more about MetaVia's insider trading history. Receive MTVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MetaVia and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MTVA Stock News HeadlinesMetaVia Inc.: MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of ObesityJuly 9, 2026 | finanznachrichten.deMetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of ObesityJuly 9, 2026 | prnewswire.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.July 13 at 1:00 AM | InvestorPlace (Ad)MetaVia Announces $4 Million At-The-Market Stock OfferingJuly 2, 2026 | tipranks.comMTVA: Vanoglipel and DA-1726 Data Presented at ADA 2026 Scientific SessionsJune 17, 2026 | finance.yahoo.comMetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor ForumJune 17, 2026 | prnewswire.comBioStem Technologies Announces Appointment of Three New Members to its Board of DirectorsJune 9, 2026 | globenewswire.comMetaVia Shareholders Approve Equity Plan and Reverse SplitJune 8, 2026 | tipranks.comSee More Headlines MTVA Stock Analysis - Frequently Asked Questions How have MTVA shares performed this year? MetaVia's stock was trading at $8.42 on January 1st, 2026. Since then, MTVA shares have decreased by 78.9% and is now trading at $1.78. How were MetaVia's earnings last quarter? MetaVia Inc. (NASDAQ:MTVA) issued its quarterly earnings results on Thursday, May, 14th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by $0.03. When did MetaVia's stock split? Shares of MetaVia reverse split on Friday, December 5th 2025.The 1-11 reverse split was announced on Tuesday, December 2nd 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split. When did MetaVia IPO? MetaVia (MTVA) raised $36 million in an IPO on Thursday, June 23rd 2016. The company issued 3,000,000 shares at $11.00-$13.00 per share. How do I buy shares of MetaVia? Shares of MTVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/14/2026Today7/13/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 MTVA's financial health is in the Yellow zone, according to TradeSmith. MTVA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MTVA Previous SymbolNASDAQ:NRBO CIK1638287 Webwww.neurobopharma.com Phone857-702-9600Fax734-293-0444Employees8Year FoundedN/APrice Target and Rating Average Price Target for MetaVia$20.00 High Price Target$20.00 Low Price Target$20.00 Potential Upside/Downside+1,023.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($5.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-172.92% Return on Assets-89.39% Debt Debt-to-Equity RatioN/A Current Ratio2.73 Quick Ratio2.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.31 per share Price / Book0.77Miscellaneous Outstanding Shares5,160,000Free Float5,133,000Market Cap$9.18 million OptionableN/A Beta0.97 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:MTVA) was last updated on 7/13/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MetaVia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MetaVia With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
